IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER
Carcinoma, Pancreatic Ductal
OHSU Knight Cancer Institutemonoclonal_antibodyPhase 2Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 89/ 100
Competitive context
282 Active assets in the Carcinoma, Pancreatic Ductal cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan NRG Oncology | Phase 3 | BB |
Daraxonrasib Revolution Medicines, Inc. | Phase 3 | BB |
Rmc-6236 Tango Therapeutics, Inc. | Phase 3 | BB |
S-1 Genentech, Inc. | Phase 2 | BB |
Metformin British Columbia Cancer Agency | Phase 2 | BB |
View all 50 →
Same molecule, other indications
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →